- Email: [email protected]
SAFETY AND EFFICACY OF DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH PERSISTENT AND LONG-ACTING ATRIAL FIBRILLATION UNDERGOING ELECTRICAL CARDIOVERSION
A328 JACC April 1, 2014 Volume 63, Issue 12
Arrhythmias and Clinical EP Safety and Efficacy of Dabigatran versus Warfarin in Patients with Persistent and LongActing Atrial Fibrillation Undergoing Electrical Cardioversion Poster Contributions Hall C Saturday, March 29, 2014, 10:00 a.m.-10:45 a.m.
Session Title: Arrhythmias and Clinical EP: State of the Art Anticoagulation for Atrial Fibrillation Abstract Category: 4. Arrhythmias and Clinical EP: AF/SVT Presentation Number: 1109-118 Authors: Oskars Kalejs, Sandis Sakne, Olga Litunenko, Aldis Strelnieks, Maija Vikmane, Marina Kovalova, Ginta Kamzola, Milana Zabunova, Kaspars Kupics, Aivars Lejnieks, Andrejs Erglis, Riga Stradins University, Riga, Latvia, Latvian Centre of Cardiology, Riga, Latvia Background: Oral anticoagulant (OAC) therapy is the most important factor for safety and efficacy for patients with atrial fibrillation (AF) undergoing electrical cardioversion (ECV). Dabigatran is a possible alternative OAC before and after ECV vs warfarin. Methods: We have analysed the data collected before, during and after ECV in 588 patients (pts). All patients had AF, 525 defined as persistent and 63 defined as long-acting, mean CHA2DS2VASc score was 3±1.8, 300 had one or two ECV in anamnesis. 324 (55.1%) pts started the use of dabigatran (150 mg twice) before ECV for at least 21 day, 264 (44.9%) started warfarin therapy and 21 day start after INR was in range 2.0 - 3.0. Precardioversion transesophageal echocardiography (TEE) was encouraged in both groups for pts with CHA2DS2VASc score ≥ 3, markedly left atrial dilatation and AF duration ≥ 6 months. Electrocardiography and echocardiography data were analysed 30 and 90 days after ECV. Results: ECV was successful after first shock in 540 (91.2%) pts, in total successful ECV in 577 (98.1%) pts. Left atrial thrombi were detected on TEE before ECV in five pts in dabigatran group and seven pts in warfarin group, so, pts continued OAC therapy for one month, and TEE had been performed again after. Two pts in dabigatran group and two pts in warfarin group were free of thrombus and have been referred to ECV. Average time for treatment before ECV was significantly lower for dabigatran (25 days) vs warfarin (35 days, p<0.01). Stroke and systemic embolism rates at 90 days were lower in dabigatran group (0.1%) vs warfarin group (0.7%). There was no difference of events between TEE and non-TEE pts. Dabigatran pts had significantly lower clinical relevant bleeding rate vs warfarin (D 0.6% vs W 2.8%, p<0.04) and better compliance. Conclusion: Dabigatran 150 mg twice is a safe, effective and reasonable alternative to warfarin for patients undergoing ECV despite CHA2DS2VASc risk score and AF duration. The frequencies of stroke and embolic events were lower in dabigatran 150 mg versus warfarin with lower major bleeding within 30 and 90 days after ECV. Patients undergoing dabigatran therapy have shorter time before procedures and can save time for INR test in normal range.
Arrhythmias and Clinical EP Safety and Efficacy of Dabigatran versus Warfarin in Patients with Persistent and LongActing Atrial Fibrillation Undergoing Electrical Cardioversion Poster Contributions Hall C Saturday, March 29, 2014, 10:00 a.m.-10:45 a.m.
Session Title: Arrhythmias and Clinical EP: State of the Art Anticoagulation for Atrial Fibrillation Abstract Category: 4. Arrhythmias and Clinical EP: AF/SVT Presentation Number: 1109-118 Authors: Oskars Kalejs, Sandis Sakne, Olga Litunenko, Aldis Strelnieks, Maija Vikmane, Marina Kovalova, Ginta Kamzola, Milana Zabunova, Kaspars Kupics, Aivars Lejnieks, Andrejs Erglis, Riga Stradins University, Riga, Latvia, Latvian Centre of Cardiology, Riga, Latvia Background: Oral anticoagulant (OAC) therapy is the most important factor for safety and efficacy for patients with atrial fibrillation (AF) undergoing electrical cardioversion (ECV). Dabigatran is a possible alternative OAC before and after ECV vs warfarin. Methods: We have analysed the data collected before, during and after ECV in 588 patients (pts). All patients had AF, 525 defined as persistent and 63 defined as long-acting, mean CHA2DS2VASc score was 3±1.8, 300 had one or two ECV in anamnesis. 324 (55.1%) pts started the use of dabigatran (150 mg twice) before ECV for at least 21 day, 264 (44.9%) started warfarin therapy and 21 day start after INR was in range 2.0 - 3.0. Precardioversion transesophageal echocardiography (TEE) was encouraged in both groups for pts with CHA2DS2VASc score ≥ 3, markedly left atrial dilatation and AF duration ≥ 6 months. Electrocardiography and echocardiography data were analysed 30 and 90 days after ECV. Results: ECV was successful after first shock in 540 (91.2%) pts, in total successful ECV in 577 (98.1%) pts. Left atrial thrombi were detected on TEE before ECV in five pts in dabigatran group and seven pts in warfarin group, so, pts continued OAC therapy for one month, and TEE had been performed again after. Two pts in dabigatran group and two pts in warfarin group were free of thrombus and have been referred to ECV. Average time for treatment before ECV was significantly lower for dabigatran (25 days) vs warfarin (35 days, p<0.01). Stroke and systemic embolism rates at 90 days were lower in dabigatran group (0.1%) vs warfarin group (0.7%). There was no difference of events between TEE and non-TEE pts. Dabigatran pts had significantly lower clinical relevant bleeding rate vs warfarin (D 0.6% vs W 2.8%, p<0.04) and better compliance. Conclusion: Dabigatran 150 mg twice is a safe, effective and reasonable alternative to warfarin for patients undergoing ECV despite CHA2DS2VASc risk score and AF duration. The frequencies of stroke and embolic events were lower in dabigatran 150 mg versus warfarin with lower major bleeding within 30 and 90 days after ECV. Patients undergoing dabigatran therapy have shorter time before procedures and can save time for INR test in normal range.